CELU
Price
$2.96
Change
-$0.20 (-6.33%)
Updated
Jul 25 closing price
Capitalization
70.89M
RNAC
Price
$13.33
Change
-$0.13 (-0.97%)
Updated
Jul 25 closing price
Capitalization
345.97M
Interact to see
Advertisement

CELU vs RNAC

Header iconCELU vs RNAC Comparison
Open Charts CELU vs RNACBanner chart's image
Celularity
Price$2.96
Change-$0.20 (-6.33%)
Volume$138.01K
Capitalization70.89M
Cartesian Therapeutics
Price$13.33
Change-$0.13 (-0.97%)
Volume$38.76K
Capitalization345.97M
CELU vs RNAC Comparison Chart in %
Loading...
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELU vs. RNAC commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELU is a Hold and RNAC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (CELU: $2.96 vs. RNAC: $13.33)
Brand notoriety: CELU and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELU: 47% vs. RNAC: 56%
Market capitalization -- CELU: $70.89M vs. RNAC: $345.97M
CELU [@Biotechnology] is valued at $70.89M. RNAC’s [@Biotechnology] market capitalization is $345.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELU’s FA Score shows that 0 FA rating(s) are green whileRNAC’s FA Score has 1 green FA rating(s).

  • CELU’s FA Score: 0 green, 5 red.
  • RNAC’s FA Score: 1 green, 4 red.
According to our system of comparison, RNAC is a better buy in the long-term than CELU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELU’s TA Score shows that 7 TA indicator(s) are bullish while RNAC’s TA Score has 7 bullish TA indicator(s).

  • CELU’s TA Score: 7 bullish, 4 bearish.
  • RNAC’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RNAC is a better buy in the short-term than CELU.

Price Growth

CELU (@Biotechnology) experienced а -2.31% price change this week, while RNAC (@Biotechnology) price change was +12.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

CELU is expected to report earnings on May 08, 2025.

RNAC is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNAC($346M) has a higher market cap than CELU($70.9M). CELU YTD gains are higher at: 42.308 vs. RNAC (-25.572). CELU has higher annual earnings (EBITDA): -21.59M vs. RNAC (-83.55M). RNAC has more cash in the bank: 180M vs. CELU (133K). RNAC has less debt than CELU: RNAC (14.1M) vs CELU (69.1M). CELU has higher revenues than RNAC: CELU (48.2M) vs RNAC (34.2M).
CELURNACCELU / RNAC
Capitalization70.9M346M20%
EBITDA-21.59M-83.55M26%
Gain YTD42.308-25.572-165%
P/E RatioN/A2.50-
Revenue48.2M34.2M141%
Total Cash133K180M0%
Total Debt69.1M14.1M490%
FUNDAMENTALS RATINGS
CELU vs RNAC: Fundamental Ratings
CELU
RNAC
OUTLOOK RATING
1..100
3110
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3649
P/E GROWTH RATING
1..100
10021
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELU's Valuation (60) in the null industry is somewhat better than the same rating for RNAC (99) in the Biotechnology industry. This means that CELU’s stock grew somewhat faster than RNAC’s over the last 12 months.

CELU's Profit vs Risk Rating (100) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that CELU’s stock grew similarly to RNAC’s over the last 12 months.

CELU's SMR Rating (99) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that CELU’s stock grew similarly to RNAC’s over the last 12 months.

CELU's Price Growth Rating (36) in the null industry is in the same range as RNAC (49) in the Biotechnology industry. This means that CELU’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's P/E Growth Rating (21) in the Biotechnology industry is significantly better than the same rating for CELU (100) in the null industry. This means that RNAC’s stock grew significantly faster than CELU’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELURNAC
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 9 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
CELU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TOKUY9.45N/A
N/A
Tokyu Corp.
RVTI0.02N/A
N/A
Rival Technologies, Inc.
RSDEF2.39N/A
N/A
Ramsdens Holdings PLC
TRUBF5.44N/A
N/A
TRUECALLER AB
CMPGY35.46-0.25
-0.70%
Compass Group Plc

CELU and

Correlation & Price change

A.I.dvisor tells us that CELU and FATE have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and FATE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELU
1D Price
Change %
CELU100%
-6.33%
FATE - CELU
27%
Poorly correlated
-0.80%
PRAX - CELU
27%
Poorly correlated
+2.09%
RNAC - CELU
26%
Poorly correlated
-0.97%
SAGE - CELU
26%
Poorly correlated
+0.46%
SPRO - CELU
26%
Poorly correlated
-0.85%
More